Urban Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Urban Wealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Buy	+18	New	+$1.71K	﹤0.01%	341

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Urban Wealth Management's HZNP Position: Q2 2022 in Review

Urban Wealth Management opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022: 18 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #341 among its holdings.

616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Urban Wealth Management held 18 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $1K as of Q2 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares was a new Urban Wealth Management position in Q2 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Urban Wealth Management's portfolio in Q2 2022, its #341 holding.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Urban Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.